Experimental combo aims to fight Hard-to-Treat cancers

NCT ID NCT06468358

Recruiting now Disease control Sponsor: L & L Bio Co., Ltd., Ningbo, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests two experimental drugs, LB1410 and LB4330, given together to people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find safe doses and to see if the combination can shrink tumors or slow their growth. About 194 participants will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LB1410 (a drug that targets PD-1 and TIM3) and LB4330 (a drug that targets claudin18.2 and carries IL-10)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard options.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the combination may not prove effective or safe enough for wider use. Side effects from the immune-targeting drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 201114, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.